{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"132","value":"398"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"309"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Atezolizumab + Bevacizumab - Global"}],"paramType":"MEAN","populationDescription":"The Global pharmacokinetic (PK)-evaluable population was defined as all participants in the Global population who received any dose of study treatment and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","timeFrame":"Post-dose on Day 1 of Cycle 1 (cycle length = 21 days)","title":"Maximum Serum Concentration (Cmax) of Atezolizumab at Cycle 1 in the Global Population","type":"SECONDARY","unitOfMeasure":"micrograms/milliliter (mcg/mL)"}